Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Biomarker Study

CONCLUSIONS: After this study is completed, we will have further evidence on whether a highly purified EPA is effective in reducing cardiovascular events for secondary prevention or not, as well as whether if EPA/AA ratio is a predictor for future cardiovascular events.PMID:36372250 | DOI:10.1016/j.ahj.2022.11.008

Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Yuji Nishizaki Katsumi Miyauchi Hiroshi Iwata Teruo Inoue Atsushi Hirayama Kazuo Kimura Yukio Ozaki Toyoaki Murohara Kenji Ueshima Yoshihiro Kuwabara Sachiko Tanaka-Mizuno Naotake Yanagisawa Tosiya Sato Hiroyuki Daida Source Type: research